INDSWFTLABBSEIND SWIFT LABORATORIES LT· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 10 Aug, 2026 · 19:38 IST

Ind-Swift Labs Q1 PAT jumps 3x to Rs 24.4 Cr; revenue up 21% YoY, sells land for Rs 17.5 Cr

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDFExplain this filing

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+19.1%Reaction day
₹239.00
prior close
₹266.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.2%+19.3% vs market
Pharmaceuticals peers, median of 164sector+0.1%+19.0% vs sector

On the reaction day the stock moved 19.3 pts more than Nifty Microcap 250 and 19.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.2
10m
+5.6
15m
+5.2
30m
+5.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+19.1-0.2+19.3+0.1+19.0
Next day
+25.7+0.2+25.5-0.5+26.2
2d
+24.1+0.4+23.7+0.1+24.0
3d
+27.2+0.4+26.8-0.5+27.7
4d
+32.0+0.6+31.5-1.1+33.1
5d
+46.4+0.9+45.5-0.7+47.2
1w
+39.3+0.9+38.5-1.2+40.5
15d
+52.5+0.9+51.6-0.8+53.3
1m
+62.8+2.3+60.4+0.9+61.8
2m
+51.5-1.1+52.6-3.1+54.6
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 standalone revenue from operations rose 21% YoY to Rs 186.08 Cr. Net profit tripled to Rs 24.44 Cr from Rs 8.12 Cr. EBITDA surged to Rs 33.32 Cr vs Rs 8.44 Cr. Consolidated net profit at Rs 24.68 Cr. Board also approved sale of 10-acre Punjab land for Rs 17.50 Cr over 9 months, land found unsuitable for pharma facility. Auditor review unqualified.

Likely market impact

Strong earnings beat with 3x PAT growth and EBITDA expansion signals operational turnaround. Land sale adds Rs 17.5 Cr cash inflow.